首页> 外文OA文献 >A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

【2h】

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

机译：双盲，安慰剂控制的期II研究，以确定具有DSM-5注意力/多动障碍（ADHD）的成人MAZINDOL的受控释放（CR）制剂的疗效，安全性，耐受性和药代动力学（ADHD）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tim L. Wigal; Jeffrey H. Newcorn; Nelson Handal; Sharon B. Wigal; Ioulietta Mulligan; Virginia Schmith; Eric Konofal;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) [J] . Tim L. Wigal, Jeffrey H. Newcorn, Nelson Handal, CNS drugs . 2018,第3期

机译：双盲，安慰剂控制的期II研究，以确定具有DSM-5注意力/多动障碍（ADHD）的成人MAZINDOL的受控释放（CR）制剂的疗效，安全性，耐受性和药代动力学（ADHD）
2. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder [J] . The journal of clinical psychiatry . 2012,第12期

机译：一项随机，双盲，安慰剂对照的多中心研究，评估了注意力缺陷多动障碍成年人中缓释美多辛的疗效，安全性和耐受性
3. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study [J] . Ginsberg Y., Arngrim T., Philipsen A., CNS drugs . 2014,第10期

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周，灵活剂量，开放标签扩展至40-周，双盲，随机，安慰剂对照核心研究
4. A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy Safety Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) [O] . Tim L. Wigal, Jeffrey H. Newcorn, Nelson Handal, -1

机译：一项双盲安慰剂对照的II期研究用于确定DSM-5注意缺陷/多动障碍（ADHD）成年人中Mazindol控释（CR）制剂的功效安全性耐受性和药代动力学
5. Long-Term (1 Year) Safety and Efficacy of Methylphenidate Modified-Release Long-Acting Formulation (MPH-LA) in Adults with Attention-Deficit Hyperactivity Disorder: A 26-Week, Flexible-Dose, Open-Label Extension to a 40-Week, Double-Blind, Randomised, Placebo-Controlled Core Study [O] . 2014

机译：患有注意力缺陷多动障碍的成年人的哌醋甲酯修饰释放长效制剂（MPH-LA）的长期（1年）安全性和有效性：26周，灵活剂量，开放标签扩展到40-周，双盲，随机，安慰剂对照核心研究

A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)

著录项

引文网络

相似文献

相关主题

期刊订阅